Global Blood Therapeutics (Global Blood Therapeutics) Change In Receivables : $-10.2 Mil (TTM As of Jun. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics Change In Receivables?

Global Blood Therapeutics's change in receivables for the quarter that ended in Jun. 2022 was $-2.0 Mil. It means Global Blood Therapeutics's Accounts Receivable increased by $2.0 Mil from Mar. 2022 to Jun. 2022 .

Global Blood Therapeutics's change in receivables for the fiscal year that ended in Dec. 2021 was $-11.3 Mil. It means Global Blood Therapeutics's Accounts Receivable increased by $11.3 Mil from Dec. 2020 to Dec. 2021 .

Global Blood Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2022 was $29.8 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Global Blood Therapeutics's Days Sales Outstanding for the three months ended in Jun. 2022 was 37.96.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Global Blood Therapeutics's liquidation value for the three months ended in Jun. 2022 was $-179.7 Mil.

Global Blood Therapeutics Change In Receivables Historical Data

The historical data trend for Global Blood Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Blood Therapeutics Change In Receivables Chart

Global Blood Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Receivables

Get a 7-Day Free Trial

-2.64

-14.86

-11.30

Global Blood Therapeutics Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Change In Receivables	Get a 7-Day Free Trial															-1.28	-4.35	-4.91	1.07	-2.04

Global Blood Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.2 Mil.

Global Blood Therapeutics (NAS:GBT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Global Blood Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	29.765	/	71.55	*	91
=	37.96

2. In Ben Graham's calculation of liquidation value, Global Blood Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Global Blood Therapeutics's liquidation value for the quarter that ended in Jun. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	517.158	-	752.082	+	0.75 * 29.765	+	0.5 * 65.816
=	-179.7

Global Blood Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.gbt.com

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Executives

Jeffrey S Farrow	officer: Chief Financial Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo	director	ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik	officer: Chief Human Resources Officer	6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink	officer: Chief Human Resources Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers	officer: Chief Scientific Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry	director	176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love	director, officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari	officer: Chief Legal Officer	3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr.	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080